A new review published in Regulatory Toxicology and Pharmacology highlights the urgent need for international regulatory bodies to update guidelines on nonclinical efficacy testing for antidepressants. The study, authored by PETA scientists and advocates across the world, including AFSA CEO Rachel Smith, emphasises the shortcomings of traditional animal tests, specifically